Athira Pharma (LONA) Competitors

$10.33 0.00 (0.00%)

Closing price 05/22/2026 04:00 PM Eastern

Extended Trading

$10.48 +0.15 (+1.40%)

As of 05/22/2026 04:10 PM Eastern

LONA vs. IRD, PBYI, XFOR, CMPX, and FENC

Should you buy Athira Pharma stock or one of its competitors? MarketBeat compares Athira Pharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Athira Pharma include Opus Genetics (IRD), Puma Biotechnology (PBYI), X4 Pharmaceuticals (XFOR), Compass Therapeutics (CMPX), and Adherex Technologies (FENC). These companies are all part of the "pharmaceutical products" industry.

How does Athira Pharma compare to Opus Genetics?

Athira Pharma (NASDAQ:LONA) and Opus Genetics (NASDAQ:IRD) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, media sentiment, risk, valuation and profitability.

Athira Pharma currently has a consensus target price of $10.00, suggesting a potential downside of 3.19%. Opus Genetics has a consensus target price of $10.18, suggesting a potential upside of 139.01%. Given Opus Genetics' stronger consensus rating and higher probable upside, analysts plainly believe Opus Genetics is more favorable than Athira Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Athira Pharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Opus Genetics	2 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.80

57.1% of Athira Pharma shares are owned by institutional investors. Comparatively, 15.0% of Opus Genetics shares are owned by institutional investors. 25.7% of Athira Pharma shares are owned by company insiders. Comparatively, 11.7% of Opus Genetics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Athira Pharma has a beta of 1.98, suggesting that its share price is 98% more volatile than the broader market. Comparatively, Opus Genetics has a beta of 0.62, suggesting that its share price is 38% less volatile than the broader market.

In the previous week, Opus Genetics had 6 more articles in the media than Athira Pharma. MarketBeat recorded 6 mentions for Opus Genetics and 0 mentions for Athira Pharma. Opus Genetics' average media sentiment score of 0.40 beat Athira Pharma's score of 0.00 indicating that Opus Genetics is being referred to more favorably in the news media.

Company	Overall Sentiment
Athira Pharma	Neutral
Opus Genetics	Neutral

Athira Pharma has a net margin of 0.00% compared to Opus Genetics' net margin of -892.36%. Opus Genetics' return on equity of -338.88% beat Athira Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Athira Pharma	N/A	-381.01%	-225.74%
Opus Genetics	-892.36%	-338.88%	-191.21%

Opus Genetics has higher revenue and earnings than Athira Pharma. Opus Genetics is trading at a lower price-to-earnings ratio than Athira Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Athira Pharma	N/A	N/A	-$105.61M	-$5.21	N/A
Opus Genetics	$14.20M	24.42	-$49.59M	-$1.33	N/A

Summary

Opus Genetics beats Athira Pharma on 11 of the 16 factors compared between the two stocks.

How does Athira Pharma compare to Puma Biotechnology?

Athira Pharma (NASDAQ:LONA) and Puma Biotechnology (NASDAQ:PBYI) are both small-cap pharmaceutical products companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, dividends, media sentiment, analyst recommendations, institutional ownership, earnings, risk and profitability.

57.1% of Athira Pharma shares are owned by institutional investors. Comparatively, 61.3% of Puma Biotechnology shares are owned by institutional investors. 25.7% of Athira Pharma shares are owned by insiders. Comparatively, 22.2% of Puma Biotechnology shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Athira Pharma's average media sentiment score of 0.00 equaled Puma Biotechnology'saverage media sentiment score.

Company	Overall Sentiment
Athira Pharma	Neutral
Puma Biotechnology	Neutral

Puma Biotechnology has higher revenue and earnings than Athira Pharma. Athira Pharma is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Athira Pharma	N/A	N/A	-$105.61M	-$5.21	N/A
Puma Biotechnology	$228.40M	1.58	$31.11M	$0.48	14.75

Athira Pharma presently has a consensus price target of $10.00, suggesting a potential downside of 3.19%. Given Athira Pharma's stronger consensus rating and higher possible upside, equities research analysts clearly believe Athira Pharma is more favorable than Puma Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Athira Pharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Puma Biotechnology	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Athira Pharma has a beta of 1.98, suggesting that its share price is 98% more volatile than the broader market. Comparatively, Puma Biotechnology has a beta of 1.24, suggesting that its share price is 24% more volatile than the broader market.

Puma Biotechnology has a net margin of 10.69% compared to Athira Pharma's net margin of 0.00%. Puma Biotechnology's return on equity of 20.30% beat Athira Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Athira Pharma	N/A	-381.01%	-225.74%
Puma Biotechnology	10.69%	20.30%	12.05%

Summary

Puma Biotechnology beats Athira Pharma on 8 of the 13 factors compared between the two stocks.

How does Athira Pharma compare to X4 Pharmaceuticals?

X4 Pharmaceuticals (NASDAQ:XFOR) and Athira Pharma (NASDAQ:LONA) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, analyst recommendations, earnings, valuation, dividends and institutional ownership.

X4 Pharmaceuticals presently has a consensus target price of $8.50, indicating a potential upside of 110.40%. Athira Pharma has a consensus target price of $10.00, indicating a potential downside of 3.19%. Given X4 Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe X4 Pharmaceuticals is more favorable than Athira Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
X4 Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Athira Pharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

X4 Pharmaceuticals has higher revenue and earnings than Athira Pharma. Athira Pharma is trading at a lower price-to-earnings ratio than X4 Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
X4 Pharmaceuticals	$35.11M	10.85	-$79.20M	-$4.54	N/A
Athira Pharma	N/A	N/A	-$105.61M	-$5.21	N/A

In the previous week, X4 Pharmaceuticals had 1 more articles in the media than Athira Pharma. MarketBeat recorded 1 mentions for X4 Pharmaceuticals and 0 mentions for Athira Pharma. X4 Pharmaceuticals' average media sentiment score of 0.00 equaled Athira Pharma'saverage media sentiment score.

Company	Overall Sentiment
X4 Pharmaceuticals	Neutral
Athira Pharma	Neutral

72.0% of X4 Pharmaceuticals shares are held by institutional investors. Comparatively, 57.1% of Athira Pharma shares are held by institutional investors. 1.1% of X4 Pharmaceuticals shares are held by insiders. Comparatively, 25.7% of Athira Pharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

X4 Pharmaceuticals has a beta of 0.31, indicating that its share price is 69% less volatile than the broader market. Comparatively, Athira Pharma has a beta of 1.98, indicating that its share price is 98% more volatile than the broader market.

Athira Pharma has a net margin of 0.00% compared to X4 Pharmaceuticals' net margin of -1,106.30%. X4 Pharmaceuticals' return on equity of -94.90% beat Athira Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
X4 Pharmaceuticals	-1,106.30%	-94.90%	-48.09%
Athira Pharma	N/A	-381.01%	-225.74%

Summary

X4 Pharmaceuticals beats Athira Pharma on 11 of the 14 factors compared between the two stocks.

How does Athira Pharma compare to Compass Therapeutics?

Athira Pharma (NASDAQ:LONA) and Compass Therapeutics (NASDAQ:CMPX) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, earnings, media sentiment, profitability, valuation and dividends.

Compass Therapeutics' return on equity of -39.75% beat Athira Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Athira Pharma	N/A	-381.01%	-225.74%
Compass Therapeutics	N/A	-39.75%	-35.29%

57.1% of Athira Pharma shares are owned by institutional investors. Comparatively, 68.4% of Compass Therapeutics shares are owned by institutional investors. 25.7% of Athira Pharma shares are owned by company insiders. Comparatively, 18.7% of Compass Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Compass Therapeutics has higher revenue and earnings than Athira Pharma. Compass Therapeutics is trading at a lower price-to-earnings ratio than Athira Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Athira Pharma	N/A	N/A	-$105.61M	-$5.21	N/A
Compass Therapeutics	$850K	438.57	-$66.49M	-$0.41	N/A

In the previous week, Compass Therapeutics had 7 more articles in the media than Athira Pharma. MarketBeat recorded 7 mentions for Compass Therapeutics and 0 mentions for Athira Pharma. Compass Therapeutics' average media sentiment score of 0.28 beat Athira Pharma's score of 0.00 indicating that Compass Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Athira Pharma	Neutral
Compass Therapeutics	Neutral

Athira Pharma currently has a consensus target price of $10.00, suggesting a potential downside of 3.19%. Compass Therapeutics has a consensus target price of $13.60, suggesting a potential upside of 557.00%. Given Compass Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Compass Therapeutics is more favorable than Athira Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Athira Pharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Compass Therapeutics	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86

Athira Pharma has a beta of 1.98, suggesting that its share price is 98% more volatile than the broader market. Comparatively, Compass Therapeutics has a beta of 0.79, suggesting that its share price is 21% less volatile than the broader market.

Summary

Compass Therapeutics beats Athira Pharma on 12 of the 15 factors compared between the two stocks.

How does Athira Pharma compare to Adherex Technologies?

Athira Pharma (NASDAQ:LONA) and Adherex Technologies (NASDAQ:FENC) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, media sentiment, dividends, profitability, analyst recommendations, valuation, institutional ownership and earnings.

Athira Pharma presently has a consensus price target of $10.00, indicating a potential downside of 3.19%. Adherex Technologies has a consensus price target of $15.40, indicating a potential upside of 55.09%. Given Adherex Technologies' stronger consensus rating and higher probable upside, analysts plainly believe Adherex Technologies is more favorable than Athira Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Athira Pharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Adherex Technologies	2 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.57

Adherex Technologies has higher revenue and earnings than Athira Pharma. Adherex Technologies is trading at a lower price-to-earnings ratio than Athira Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Athira Pharma	N/A	N/A	-$105.61M	-$5.21	N/A
Adherex Technologies	$44.64M	7.68	-$9.74M	-$0.29	N/A

In the previous week, Adherex Technologies had 14 more articles in the media than Athira Pharma. MarketBeat recorded 14 mentions for Adherex Technologies and 0 mentions for Athira Pharma. Athira Pharma's average media sentiment score of 0.00 beat Adherex Technologies' score of -0.27 indicating that Athira Pharma is being referred to more favorably in the media.

Company	Overall Sentiment
Athira Pharma	Neutral
Adherex Technologies	Neutral

Athira Pharma has a beta of 1.98, meaning that its stock price is 98% more volatile than the broader market. Comparatively, Adherex Technologies has a beta of 0.91, meaning that its stock price is 9% less volatile than the broader market.

Athira Pharma has a net margin of 0.00% compared to Adherex Technologies' net margin of -17.12%. Adherex Technologies' return on equity of -43.87% beat Athira Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Athira Pharma	N/A	-381.01%	-225.74%
Adherex Technologies	-17.12%	-43.87%	-11.35%

57.1% of Athira Pharma shares are owned by institutional investors. Comparatively, 55.5% of Adherex Technologies shares are owned by institutional investors. 25.7% of Athira Pharma shares are owned by insiders. Comparatively, 10.7% of Adherex Technologies shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Adherex Technologies beats Athira Pharma on 10 of the 16 factors compared between the two stocks.

Get Athira Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LONA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LONA vs. The Competition

Export

Metric	Athira Pharma	Biological Products, Except Diagnostic Substances Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$97.03M	$431.65M	$4.26B	$12.34B
Dividend Yield	N/A	N/A	5.93%	5.28%
P/E Ratio	-1.98	N/A	21.90	25.65
Price / Sales	N/A	326.53	180.55	86.28
Price / Cash	N/A	N/A	55.68	56.67
Price / Book	1.97	3.25	34.85	7.14
Net Income	-$105.61M	-$81.71M	$112.32M	$335.98M
7 Day Performance	2.38%	2.74%	3.52%	4.15%
1 Month Performance	24.01%	2.02%	3.56%	2.54%
1 Year Performance	N/A	N/A	15.78%	35.05%

Athira Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LONA Athira Pharma	1.5606 of 5 stars	$10.33 flat	$10.00 -3.2%	N/A	$97.03M	N/A	N/A	40
IRD Opus Genetics	3.4943 of 5 stars	$4.29 -3.4%	$10.18 +137.3%	+317.6%	$361.40M	$14.20M	N/A	14	Gap Up
PBYI Puma Biotechnology	1.2957 of 5 stars	$7.05 +0.9%	N/A	+119.2%	$355.79M	$228.40M	14.69	200
XFOR X4 Pharmaceuticals	2.197 of 5 stars	$4.04 +7.2%	$8.50 +110.4%	+30.3%	$355.58M	$35.11M	N/A	80	Analyst Upgrade
CMPX Compass Therapeutics	3.23 of 5 stars	$1.92 +1.6%	$13.60 +608.3%	-1.0%	$340.37M	$850K	N/A	20

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LONA) was last updated on 5/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Athira Pharma (LONA) Competitors

LONA vs. IRD, PBYI, XFOR, CMPX, and FENC

How does Athira Pharma compare to Opus Genetics?

Summary

How does Athira Pharma compare to Puma Biotechnology?

Summary

How does Athira Pharma compare to X4 Pharmaceuticals?

Summary

How does Athira Pharma compare to Compass Therapeutics?

Summary

How does Athira Pharma compare to Adherex Technologies?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LONA vs. The Competition

Athira Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Athira Pharma (LONA) Competitors

LONA vs. IRD, PBYI, XFOR, CMPX, and FENC

How does Athira Pharma compare to Opus Genetics?

Do analysts recommend LONA or IRD?

Do institutionals & insiders have more ownership in LONA or IRD?

Which has more volatility and risk, LONA or IRD?

Does the media favor LONA or IRD?

Is LONA or IRD more profitable?

Which has higher valuation and earnings, LONA or IRD?

Summary

How does Athira Pharma compare to Puma Biotechnology?

Do institutionals and insiders have more ownership in LONA or PBYI?

Does the media favor LONA or PBYI?

Which has stronger earnings & valuation, LONA or PBYI?

Do analysts prefer LONA or PBYI?

Which has more risk & volatility, LONA or PBYI?

Is LONA or PBYI more profitable?

Summary

How does Athira Pharma compare to X4 Pharmaceuticals?

Do analysts prefer XFOR or LONA?

Which has higher earnings and valuation, XFOR or LONA?

Does the media refer more to XFOR or LONA?

Do insiders and institutionals hold more shares of XFOR or LONA?

Which has more volatility & risk, XFOR or LONA?

Is XFOR or LONA more profitable?

Summary

How does Athira Pharma compare to Compass Therapeutics?

Is LONA or CMPX more profitable?

Do insiders and institutionals hold more shares of LONA or CMPX?

Which has preferable earnings & valuation, LONA or CMPX?

Does the media favor LONA or CMPX?

Do analysts prefer LONA or CMPX?

Which has more volatility & risk, LONA or CMPX?

Summary

How does Athira Pharma compare to Adherex Technologies?

Do analysts recommend LONA or FENC?

Which has preferable earnings & valuation, LONA or FENC?

Does the media favor LONA or FENC?

Which has more volatility and risk, LONA or FENC?

Is LONA or FENC more profitable?

Do insiders and institutionals believe in LONA or FENC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LONA vs. The Competition

Athira Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools